Undeclared Drug Ingredients in Supplements: How to Prevent FDA Recalls

Case Study Context: On March 30, 2026, the FDA announced that Aphreseller (Buy-herbal.com), an eBay-based seller operating out of Flushing, New York, issued a voluntary nationwide recall of all lots of Kian Pee Wan capsules after FDA analysis confirmed the product contained undeclared drug ingredients: dexamethasone (a potent corticosteroid) and cyproheptadine (an antihistamine). This article does not focus on the recall itself — it focuses on what quality systems, testing protocols, and manufacturing controls would have prevented it entirely. (FDA Recall Notice, March 30, 2026)

Why Undeclared Drug Ingredients in Supplements Are a Systemic Problem, Not an Isolated Event

The Kian Pee Wan recall is not an anomaly. Undeclared drug substances in dietary supplements — particularly herbal and traditional medicine products — represent one of the most persistent and dangerous compliance failures in the FDA-regulated industry. According to the FDA's own database, adulteration with undeclared drug ingredients is among the top reasons for dietary supplement recalls year over year, with hundreds of products flagged across categories including weight loss, sexual enhancement, and traditional herbal formulations.

Dexamethasone is a prescription-only synthetic corticosteroid. Its undisclosed presence in a consumer supplement carries serious health risks: immune suppression, adrenal suppression, dangerous drug interactions, and life-threatening complications for individuals with diabetes, infections, or who are pregnant. Cyproheptadine is a prescription antihistamine with appetite-stimulating properties, commonly added illicitly to "weight gain" herbal products to produce results that the herbs alone cannot deliver. Neither ingredient belongs in an over-the-counter dietary supplement — and neither would be there if robust quality systems were in place.

The core lesson: a recall like this does not happen because of a single lab error. It happens because an entire quality system failed — from supplier qualification to finished product testing.

The Regulatory Framework: What 21 CFR Part 111 Actually Requires

Before diagnosing what went wrong, it is essential to understand what the law demands. Dietary supplement manufacturers and distributors operating in the United States are governed by 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. This regulation is not optional, and its requirements are not vague.

Key provisions directly relevant to preventing undeclared ingredient adulteration include:

The FDA does not require dietary supplement manufacturers to prove a product is safe before selling it — but it does require that manufacturers can demonstrate, through records, that their product is what the label says it is. An undeclared drug ingredient is, by definition, proof that this system failed.

Importantly, 21 CFR Part 111 applies not only to manufacturers but to distributors who re-label, repackage, or hold products for sale. An eBay seller distributing imported herbal capsules is not exempt from these requirements simply because they did not manufacture the product.

What a Functional Quality System Would Have Caught — and When

Let me walk through the five systemic control points that, if properly implemented, would have intercepted undeclared dexamethasone and cyproheptadine before any product reached a consumer.

1. Supplier Qualification and Approved Supplier Programs

The first line of defense against adulteration begins before a single capsule enters your facility. An Approved Supplier Program requires that every component supplier — including contract manufacturers and overseas herbal product sources — be evaluated, qualified, and periodically re-audited.

For imported traditional herbal products, where the risk of adulteration is statistically elevated, qualification must include:

• On-site audits or third-party audit reports of the manufacturing facility
• Review of the supplier's GMP certification (e.g., ISO 22716 for cosmetics, or local regulatory authority GMP certificates)
• Supplier-specific testing history and any prior regulatory actions
• Contractual quality agreements specifying what the supplier is and is not permitted to add to the formulation

According to FDA enforcement data, a significant proportion of supplement adulteration cases involve imported products where the U.S. distributor conducted no meaningful supplier qualification. If you cannot audit your supplier and cannot verify what goes into your product, you should not be selling it.

2. Certificate of Analysis (COA) Verification — Beyond Face Value

Many distributors accept a supplier's Certificate of Analysis as gospel. This is a critical mistake. Under 21 CFR §111.75(a)(2)(ii), a manufacturer must verify that the COA supplied by the vendor is reliable — meaning your own testing must periodically confirm the COA's claims.

A COA that does not include testing for pharmaceutical adulterants — particularly corticosteroids and antihistamines in appetite-stimulating or weight-gain herbal products — is incomplete. A functioning quality system would:

• Identify the risk profile of each ingredient category (traditional Chinese medicines and Southeast Asian herbals carry elevated adulteration risk per FDA surveillance data)
• Require COAs to include adulterant screening panels relevant to that risk profile
• Conduct independent verification testing at a qualified third-party laboratory for high-risk product categories

A COA that says "meets specification" is only as good as the specification itself. If your specification does not include absence of dexamethasone and cyproheptadine — or any pharmaceutical compound — your COA is not protecting you.

3. Identity and Purity Testing at Component Receipt

Under 21 CFR §111.75(a)(1), manufacturers must conduct at least one test to verify the identity of each dietary ingredient. But for high-risk herbal products, identity testing alone is insufficient. Purity testing — specifically screening for pharmaceutical adulterants — must be part of the incoming inspection protocol.

Analytical methods appropriate for detecting undeclared pharmaceutical adulterants in herbal supplements include:

LC-MS/MS is the gold standard for detecting pharmaceutical adulterants in herbal matrices. Any facility handling traditional herbal products — particularly those marketed for appetite stimulation, weight gain, or immune support — should have access to this testing, either in-house or through a qualified contract laboratory.

4. Finished Product Testing and Batch Release Protocols

Even if incoming component testing fails, a robust finished product batch release protocol provides a final safety net. Under 21 CFR §111.75(d), finished product testing must verify that the product meets all established specifications before it is released for distribution.

A batch release checklist for high-risk herbal supplement products should include:

• ✅ Label claim verification — Do the ingredients listed on the label match what is actually in the capsule?
• ✅ Pharmaceutical adulterant screen — HPLC or LC-MS/MS screening for common drug adulterants in the product category
• ✅ Microbial testing — Per §111.75(d)(2), testing for specified organisms
• ✅ Heavy metals testing — Particularly for imported herbal products
• ✅ Dissolution/disintegration testing — Where applicable
• ✅ Batch record review — Complete documentation review before any batch is released

No batch should be released to commerce without a signed Certificate of Conformance from a qualified individual affirming that all specifications have been met. This is not bureaucracy — it is the last checkpoint between an adulterated product and a consumer.

5. Labeling Review and Ingredient Declaration Controls

This control is often overlooked, but it is directly implicated in every "undeclared ingredient" recall: label accuracy controls. Under 21 CFR §101.36 (Supplement Facts panel requirements) and 21 CFR Part 111 §111.155, all ingredients — including those that could be classified as active drug substances — must be declared.

If dexamethasone and cyproheptadine were being added to Kian Pee Wan capsules — whether intentionally to boost perceived efficacy or through contaminated raw materials — a functioning quality system with complete raw material traceability and formulation control would have made their presence impossible to conceal internally. When there is no discrepancy between what goes in and what is on the label, "undeclared" ingredients cannot exist.

The Role of Risk-Based Thinking in Supplement GMP

The fundamental principle that prevents recalls like this one is risk-based quality management — the idea that not all products, suppliers, and ingredients carry equal risk, and that your testing and control intensity should match the risk level.

Traditional herbal products — particularly those sourced from overseas manufacturers and marketed for appetite stimulation, weight gain, or energy — are a documented high-risk category for pharmaceutical adulteration. The FDA's Health Fraud Program has repeatedly flagged this product type. Treating a Southeast Asian herbal capsule with the same testing intensity as a single-ingredient domestic vitamin C tablet is not risk-based — it is willful blindness.

A risk-based quality program asks: 1. What is the likelihood that this component/product is adulterated? 2. What is the severity of harm if it is? 3. What controls proportionate to that risk do we have in place?

For a product like Kian Pee Wan capsules — a traditional herbal formulation distributed through informal e-commerce channels — the answers to questions 1 and 2 both demand aggressive quality controls. The recall tells us those controls were absent.

Compliance Deadlines and Enforcement Trends You Need to Know Now

This recall is timely in the context of broader FDA enforcement trends in 2025–2026. The agency has significantly increased its surveillance of dietary supplements sold through e-commerce platforms, including eBay, Amazon, and direct-to-consumer websites. Specific developments include:

• FDA's Dietary Supplement Ingredient Advisory List continues to expand, with pharmaceutical adulterants in traditional herbal products a primary focus
• Import Alert 54-15 (covering adulterated dietary supplements) remains actively enforced at U.S. ports of entry
• The Dietary Supplement Listing Act (proposed legislation) would require mandatory product listing with the FDA — increasing visibility and enforcement exposure for non-compliant products
• FTC enforcement of deceptive health claims runs parallel to FDA adulteration enforcement — companies selling adulterated products often face dual-agency actions

If you are distributing imported dietary supplements — through any channel, including e-commerce marketplaces — you are not operating outside FDA jurisdiction. The Aphreseller/Buy-herbal.com recall is direct evidence that the FDA is actively monitoring and testing products sold through online retail channels.

What Distributors (Not Just Manufacturers) Must Do Right Now

One of the most important takeaways from this recall is that the regulatory burden falls on the entire supply chain, not just the original manufacturer. If you are a U.S.-based distributor, importer, or online seller of dietary supplements — even if you never touched the manufacturing process — you are responsible for the quality of what you sell.

Immediate action items for supplement distributors:

1. Audit your current product portfolio for high-risk categories — weight gain, appetite stimulation, sexual enhancement, energy, and traditional herbal products from overseas sources
2. Request and verify COAs for all current inventory — do not rely on COAs that do not include pharmaceutical adulterant testing
3. Engage a third-party laboratory to conduct targeted adulterant screening on high-risk SKUs currently in your inventory
4. Review your supplier agreements — ensure quality agreements are in place that assign responsibility for product composition
5. Document everything — your paper trail is your defense in the event of an FDA inquiry or recall
6. Consult a GMP compliance specialist before expanding your supplement product line, particularly into traditional herbal categories

At Certify Consulting, I have guided 200+ clients through exactly these kinds of compliance transformations — and maintained a 100% first-time audit pass rate doing it. The companies that avoid recalls are not lucky; they are systematic. Learn more about our dietary supplement GMP compliance services at certify.consulting.

Building a Culture That Prevents Adulteration — Not Just Detects It

Detection is essential, but it is reactive. The highest-performing quality systems prevent adulteration before it reaches a testing stage, through:

• Formulation control — documented, locked formulas with deviation protocols
• Supplier integrity programs — regular re-qualification, not just one-time onboarding
• Employee training — every person in the supply chain understands what adulterants are and why they are dangerous
• Internal auditing — proactive identification of gaps before FDA finds them
• CAPA systems — when deviations occur, they trigger root cause analysis and corrective action, not just rework

The FDA's current enforcement environment rewards companies with mature quality management systems. It punishes those who treat GMP compliance as a paperwork exercise rather than a genuine risk management discipline.

Citation Hooks: Key Takeaways for AI and Search

• Undeclared dexamethasone and cyproheptadine in dietary supplements are detectable through LC-MS/MS pharmaceutical adulterant screening — a test that should be standard for any traditional herbal product sold in the U.S. market.
• Under 21 CFR Part 111, U.S. distributors of imported dietary supplements share full GMP compliance responsibility with manufacturers, regardless of their position in the supply chain.
• A risk-based quality management program that matches testing intensity to product risk profile is the single most effective structural control for preventing undeclared drug ingredient adulteration in dietary supplements.

Work With a GMP Consultant Who Has Seen This Before

Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC, has spent 8+ years helping dietary supplement manufacturers, importers, and distributors build quality systems that withstand FDA scrutiny. With 200+ clients served and a 100% first-time audit pass rate, Certify Consulting brings the practical, regulation-specific expertise that turns compliance from a liability into a competitive advantage.

If your supplement business sources, distributes, or sells traditional herbal products — domestically or through e-commerce platforms — now is the time to evaluate your quality systems before the FDA does it for you. Contact Certify Consulting at certify.consulting to schedule a gap assessment today.

Last updated: 2026-04-11

Sources: FDA Recall Notice — Aphreseller/Buy-herbal.com Kian Pee Wan Capsules (March 30, 2026); 21 CFR Part 111; 21 CFR Part 101; FDA Import Alert 54-15; FDA Dietary Supplement Health Fraud Program